Prognosis and Potential: How POLE and PIK3R1 Are Changing How We Approach Endometrial Cancer

In this webinar, guest speakers from Intermountain Health discuss their use of precision genomics to sequence and analyze patient tumors, and present in-depth findings on PIK3R1 and POLE in the context of endometrial cancer gleaned through the literature using the Mastermind Genomic Search Engine as part of their workflows.

PIK3R1 and POLE are emerging biomarkers in endometrial cancer. In endometrial cancer patients, PIK3R1 mutations are highly prevalent and associated with poor prognosis, but their biochemical effects in the cell remain diverse and understudied. Conversely, detection of a POLE mutation is associated with good prognosis, which can guide clinicians to spare patients from the toxicity of overtreatment. Thus, detecting and understanding these biomarkers are essential for optimizing patient care.

You Will Learn:

• How biochemical and clinical trial research may shed light on the impacts of PIK3R1 mutations in endometrial cancers
• How POLE mutations are associated with favorable prognosis and improved progression-free survival in endometrial cancer
• How the detection of a POLE mutation can spare patients the toxicity of overtreatment

Try Mastermind for yourself by creating your account: https://bit.ly/3sF4PQB Start with a free trial of Professional Edition. No payment info required.